Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886805 | PMC |
| http://dx.doi.org/10.1093/ehjcr/ytaf090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Valve Repair (OneForAll-Registry).
Catheter Cardiovasc Interv
March 2025
West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, Essen, Germany.
Background: Mitral valve transcatheter edge-to-edge repair (M-TEER) is increasingly applied in patients with high surgical risk. We aimed to evaluate whether the PASCAL system can be applied in an all-comers cohort irrespective of the underlying anatomy and whether technical features influence therapeutic success.
Methods: In this prospective, observational study we enrolled consecutive patients (n = 80) with mitral regurgitation (MR) 3+ and 4+ scheduled for M-TEER.
Right heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions.
Int J Cardiol
March 2025
HerzZentrum Hirslanden, Zurich, Switzerland.
Aims: To assess the association between right heart failure (RHF) and mortality in patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI), and to determine whether clinical RHF status reduces the survival benefit of successful versus failed TTVI.
Methods And Results: The TriValve International Registry (Transcatheter Tricuspid Valve Therapies) is a multicenter registry collecting data of patients with symptomatic, severe or greater TR undergoing TTVI. The population was stratified according to RHF status defined by the following clinical criteria: history of previous hospitalization for RHF (<1 year) OR presence of signs of RHF (jugular venous distension, ascites, peripheral oedema) OR high dose diuretic (≥125 mg/day of furosemide or equivalent).
Cardiac implantable electronic device carriers undergoing transcatheter tricuspid valve annuloplasty: real-world insights.
Clin Res Cardiol
March 2025
Heart Center, Department III of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Background: Transtricuspid cardiac implantable electronic devices (CIEDs) complicate the management of tricuspid regurgitation (TR). Transcatheter tricuspid valve annuloplasty (TTVA) offers a promising approach due to minimal interaction with leaflets and transvalvular CIEDs, though real-world evidence is limited.
Methods: This bi-center, retrospective study includes 204 consecutive patients who underwent TTVA with the Cardioband (Edwards Lifesciences) for severe symptomatic TR.
Managing Commissural Mitral Valve Regurgitation Following Transcatheter Mitral Valve Repair Using the Amplatzer Occluder Device.
Cureus
February 2025
Department of Cardiology, Henry Ford Providence Hospital, Southfield, USA.
Mitral regurgitation (MR) is a common valvular abnormality in patients in the Western world. Treatment options include surgery and edge-to-edge repair of the mitral valve leaflets using the MitraClip device. However, MR may recur, and MitraClip can be unsuccessful, posing a challenging management dilemma.
View Article and Find Full Text PDFSuccessful transcatheter edge-to-edge repair of mitral valve leaflet perforation.
Eur Heart J Case Rep
March 2025
Department of Cardiology Center, Sendai Kousei Hospital, 1-20 Tsutsumidori Amamiya, Aoba, Sendai, Miyagi 981-0914, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!